ASCO Annual Meeting

'Out of the Blue' Diagnosis Linked to a Family History of Cancer Now Empowers Others

June 12th 2019, 5:00pm

Video

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

Founding 'Faery' Shares Resources and Inspiration Behind Blue Faery Liver Cancer Association

June 11th 2019, 5:49pm

Video

Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.

Lung Cancer Stigma: A Growing Problem for Patients and Oncologists Alike

June 11th 2019, 12:09am

Article

Jennifer King, from the GO2 Foundation for Lung Cancer, discussed what patients can do to help address the stigma associated with lung cancer.

Finding the Right Tools to Improve Patient Quality of Life

June 7th 2019, 8:00pm

Article

Researchers adapted a screening tool to help treat the whole person during cancer care.

Referral Tool Helps to Identify Those at Risk for Cancer

June 7th 2019, 5:36pm

Article

A practice improvement project at the Mayo Clinic helped to increase attention to family health history and identify those at risk for cancer.

Venclexta Plus Gazyva Reduces Disease Progression by 65% in Patients with CLL

June 6th 2019, 6:51pm

Article

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

FDA's Project Facilitate Will Assist Requested Access to Unapproved Cancer Therapies

June 4th 2019, 10:32pm

Article

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

New Targeted Antibody Shows Promise for Advanced Urothelial Cancer

June 3rd 2019, 8:54pm

Article

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

Kisqali Plus Endocrine Therapy Improves Survival in Breast Cancer Subgroup

June 3rd 2019, 5:42pm

Article

The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.

Maintenance Therapy with Lynparza Delays BRCA-Positive Metastatic Pancreatic Cancer

June 3rd 2019, 5:36pm

Article

The phase 3 POLO trial is the first randomized study to establish a biomarker-driven approach in the treatment of metastatic pancreatic cancer.